Current treatment recommendations do not fully address residual risk attributable to T2D
Even with a multifactorial treatment approach according to the best standards of care, patients with T2D have substantial risk of CVD and microvascular disease.3
Aggressive therapy falls short when it comes to reducing CV risk
o In the STENO-2 study, intensive therapy reduced the risk of death from CVD by 62%; however patients still experienced CV events.12
Note: This figure illustrates the cumulative incidence of the composite cardiovascular or death endpoint.
Despite treatment with intensive, multifactorial therapy, patients still experienced events; therefore, residual risk remains.12